SCHEMBL3147555

SCHEMBL3147555

CNC(=O)C(C)c1ccc(CC(C)C)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.75
▸ PDE4A P27815 1/20 0.75
▸ CXCR1 P25024 5/20 0.69
▸ CXCR2 P25025 5/20 0.69
▸ MAPT P10636 2/20 0.68
▸ CRHBP P24387 2/20 0.68
▸ CRHR2 Q13324 2/20 0.68
▸ GAA P10253 1/20 0.68
▸ SMN1; SMN2 Q16637 1/20 0.68
▸ PTGS1 P23219 3/20 0.66
▸ PTGS2 P35354 3/20 0.66
▸ LMNA P02545 2/20 0.66
▸ CYP2C9 P11712 2/20 0.66
▸ AKR1C3 P42330 2/20 0.66
▸ ALB P02768 1/20 0.66
▸ ESR1 P03372 1/20 0.66
▸ ALOX5 P09917 1/20 0.66
▸ RARB P10826 1/20 0.66
▸ ADRB3 P13945 1/20 0.66
▸ NFKB1 P19838 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19953817 1.00 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL31006096 1.00 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL3142734 1.00 CHRM1 (0.75) CHRM1PDE4ACXCR1CXCR2MAPT
Ibuproxam SCHEMBL8722617 0.86 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2MAPT
Ibuproxam SCHEMBL24896 0.86 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2MAPT
Ibuproxam SCHEMBL10428212 0.86 CHRM1 (1.00) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL23763764 0.84 CHRM1 (0.73) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL30465076 0.84 CHRM1 (0.73) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL577665 0.84 CHRM1 (0.73) CHRM1PDE4ACXCR1CXCR2MAPT
SCHEMBL14270538 0.83 CHRM1 (0.71) CHRM1PDE4ACXCR1CXCR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3737418-B1 POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS SONY GROUP CORP (JP) 2024-02-28 — — EP disclosed
US-20160106712-A1 FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS INC (US) 2016-04-21 — — US disclosed
US-9216224-B2 Fatty acid COX inhibitor derivatives and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2015-12-22 — — US disclosed
US-20130065934-A1 FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2013-03-14 — — US disclosed
US-20100197777-A1 Synergistic combination of analgesic compounds BIOCODEX (FR) 2010-08-05 — — US disclosed
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 — — US disclosed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 — — EP disclosed
CN-100513386-C Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils DOMP S P A (IT) 2009-07-15 — — CN disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 — — US disclosed
CN-1479715-A Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils ��ķ�ɷ����޹�˾ 2004-03-03 — — CN disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 — — EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 CHRM1 1210/4885PDE4A 2262/4885CXCR1 26/4885
US-20160106712-A1 FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES PTGES, PTGES2, ALOX5 CHRM1 4707/4885PDE4A 1420/4885CXCR1 2577/4885
US-20100197777-A1 Synergistic combination of analgesic compounds OPRK1, OPRL1, OPRM1 CHRM1 420/4885PDE4A 1190/4885CXCR1 2454/4885
US-20130065934-A1 FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES PTGES, ALOX5, PTGES2 CHRM1 4634/4885PDE4A 1422/4885CXCR1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback